Cargando…
Determining Pro-Oxidant Antioxidant Balance (PAB) and Total Antioxidant Capacity (TAC) in Patients with Schizophrenia
Objective: Schizophrenia is a disease with unknown etiology. There is evidence suggesting that oxidative damage occurs in schizophrenia. Oxidative damage may arouse from imbalance between oxidant and anti-oxidant factors in cellular and tissue environment. Although it may not be the primary cause, i...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Psychiatry & Psychology Research Center, Tehran University of Medical Sciences
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6178326/ https://www.ncbi.nlm.nih.gov/pubmed/30319706 |
_version_ | 1783361945717440512 |
---|---|
author | Zahedi Avval, Farnaz Mahmoudi, Niloufar Nosrati Tirkani, Abolfazl Jarahi, Lida Hamidi Alamdari, Daryoush Sadjadi, Seyed Alireza |
author_facet | Zahedi Avval, Farnaz Mahmoudi, Niloufar Nosrati Tirkani, Abolfazl Jarahi, Lida Hamidi Alamdari, Daryoush Sadjadi, Seyed Alireza |
author_sort | Zahedi Avval, Farnaz |
collection | PubMed |
description | Objective: Schizophrenia is a disease with unknown etiology. There is evidence suggesting that oxidative damage occurs in schizophrenia. Oxidative damage may arouse from imbalance between oxidant and anti-oxidant factors in cellular and tissue environment. Although it may not be the primary cause, it can worsen the disease and may be a reason of poor response to therapy in these patients. The present study aimed at evaluating the pro-oxidant antioxidant balance (PAB) and total antioxidant capacity (TAC) in serum of schizophrenia patients. PAB is an assay to determine the pro-oxidant load and antioxidant capacity in a single measurement. Method : In this cross- sectional study, patients with diagnosis of schizophrenia, who referred to a psychiatry university hospital (Ibn-e-Sina Hospital) affiliated to Mashhad University of Medical Sciences, were enrolled. Patients' demographic characteristics and laboratory data were recorded from patients’ files. Serum PAB and TAC were measured using a special PAB assay and commercial kit, respectively. Data were analyzed using SPSS 16. Results: A total of 84 individuals (42 schizophrenia cases and 42 healthy controls) participated in this study. Controls were age and sex-matched with the patients’ group. The mean TAC in the patient and control groups was 0.49±0.04 and 0.51±0.04 nmol/L, respectively (p = 0.16). PAB was higher in patients’ group than in controls (127.36±36.44 vs. 118.93±52.34 HK), however, this difference was not statistically significant (p = 0.09). The change was correlated with the chronicity of the disease. Conclusion: Pro-oxidant antioxidant balance was elevated in serum of patients with schizophrenia. These data suggested the occurrence of oxidative stress during the progression of the disease. Lower antioxidant capacity might suggest that patients with schizophrenia could be more susceptible to oxidative stress damage. |
format | Online Article Text |
id | pubmed-6178326 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2018 |
publisher | Psychiatry & Psychology Research Center, Tehran University of Medical Sciences |
record_format | MEDLINE/PubMed |
spelling | pubmed-61783262018-10-12 Determining Pro-Oxidant Antioxidant Balance (PAB) and Total Antioxidant Capacity (TAC) in Patients with Schizophrenia Zahedi Avval, Farnaz Mahmoudi, Niloufar Nosrati Tirkani, Abolfazl Jarahi, Lida Hamidi Alamdari, Daryoush Sadjadi, Seyed Alireza Iran J Psychiatry Short Communication Objective: Schizophrenia is a disease with unknown etiology. There is evidence suggesting that oxidative damage occurs in schizophrenia. Oxidative damage may arouse from imbalance between oxidant and anti-oxidant factors in cellular and tissue environment. Although it may not be the primary cause, it can worsen the disease and may be a reason of poor response to therapy in these patients. The present study aimed at evaluating the pro-oxidant antioxidant balance (PAB) and total antioxidant capacity (TAC) in serum of schizophrenia patients. PAB is an assay to determine the pro-oxidant load and antioxidant capacity in a single measurement. Method : In this cross- sectional study, patients with diagnosis of schizophrenia, who referred to a psychiatry university hospital (Ibn-e-Sina Hospital) affiliated to Mashhad University of Medical Sciences, were enrolled. Patients' demographic characteristics and laboratory data were recorded from patients’ files. Serum PAB and TAC were measured using a special PAB assay and commercial kit, respectively. Data were analyzed using SPSS 16. Results: A total of 84 individuals (42 schizophrenia cases and 42 healthy controls) participated in this study. Controls were age and sex-matched with the patients’ group. The mean TAC in the patient and control groups was 0.49±0.04 and 0.51±0.04 nmol/L, respectively (p = 0.16). PAB was higher in patients’ group than in controls (127.36±36.44 vs. 118.93±52.34 HK), however, this difference was not statistically significant (p = 0.09). The change was correlated with the chronicity of the disease. Conclusion: Pro-oxidant antioxidant balance was elevated in serum of patients with schizophrenia. These data suggested the occurrence of oxidative stress during the progression of the disease. Lower antioxidant capacity might suggest that patients with schizophrenia could be more susceptible to oxidative stress damage. Psychiatry & Psychology Research Center, Tehran University of Medical Sciences 2018-07 /pmc/articles/PMC6178326/ /pubmed/30319706 Text en Copyright © Psychiatry & Psychology Research Center, Tehran University of Medical Sciences This is an Open Access article distributed under the terms of the Creative Commons Attribution License, (http://creativecommons.org/licenses/by/3.0/) which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Short Communication Zahedi Avval, Farnaz Mahmoudi, Niloufar Nosrati Tirkani, Abolfazl Jarahi, Lida Hamidi Alamdari, Daryoush Sadjadi, Seyed Alireza Determining Pro-Oxidant Antioxidant Balance (PAB) and Total Antioxidant Capacity (TAC) in Patients with Schizophrenia |
title | Determining Pro-Oxidant Antioxidant Balance (PAB) and Total Antioxidant Capacity (TAC) in Patients with Schizophrenia |
title_full | Determining Pro-Oxidant Antioxidant Balance (PAB) and Total Antioxidant Capacity (TAC) in Patients with Schizophrenia |
title_fullStr | Determining Pro-Oxidant Antioxidant Balance (PAB) and Total Antioxidant Capacity (TAC) in Patients with Schizophrenia |
title_full_unstemmed | Determining Pro-Oxidant Antioxidant Balance (PAB) and Total Antioxidant Capacity (TAC) in Patients with Schizophrenia |
title_short | Determining Pro-Oxidant Antioxidant Balance (PAB) and Total Antioxidant Capacity (TAC) in Patients with Schizophrenia |
title_sort | determining pro-oxidant antioxidant balance (pab) and total antioxidant capacity (tac) in patients with schizophrenia |
topic | Short Communication |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6178326/ https://www.ncbi.nlm.nih.gov/pubmed/30319706 |
work_keys_str_mv | AT zahediavvalfarnaz determiningprooxidantantioxidantbalancepabandtotalantioxidantcapacitytacinpatientswithschizophrenia AT mahmoudiniloufar determiningprooxidantantioxidantbalancepabandtotalantioxidantcapacitytacinpatientswithschizophrenia AT nosratitirkaniabolfazl determiningprooxidantantioxidantbalancepabandtotalantioxidantcapacitytacinpatientswithschizophrenia AT jarahilida determiningprooxidantantioxidantbalancepabandtotalantioxidantcapacitytacinpatientswithschizophrenia AT hamidialamdaridaryoush determiningprooxidantantioxidantbalancepabandtotalantioxidantcapacitytacinpatientswithschizophrenia AT sadjadiseyedalireza determiningprooxidantantioxidantbalancepabandtotalantioxidantcapacitytacinpatientswithschizophrenia |